| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 15 | 20 | 350 | $1,720 | $1.6M |
| G0378 | Hospital observation service, per hour | 25 | 150 | 510 | $870 | $1.4M |
| T1015 | Clinic visit/encounter, all-inclusive | 62 | 1,690 | 760 | $170 | $1.2M |
| J9271 | Injection, pembrolizumab, 1 mg | 24 | 20 | 420 | $1,230 | $827.7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17 | 130 | 310 | $60 | $769.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 30 | 210 | 730 | $40 | $689.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5 | 200 | 990 | $70 | $517.5K |
| 92507 | The provider treats a patient with communication and hearing difficulties by directly interacting with the patient. He assesses the patient with impairment in his ability to make sounds, along with… | 40 | 410 | 1,130 | $60 | $455.4K |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 62 | 1,600 | 270 | $120 | $409.7K |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 34 | 1,060 | 150 | $130 | $405.4K |